Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

Inclusion Criteria:

1. Age 18 to 75 years

2. Diagnosed with IBS-D including: a) weekly average of worst abdominal pain in the last 24 hours of ≥3 on a 0-10 scale, and b) weekly average of Bristol Stool form of ≥6 on a 1-7 scale

3. Diagnosed with functional dyspepsia defined as presence of at least one of thefollowing symptoms: bothersome postprandial fullness, early satiation, epigastricpain, or epigastric burning AND no evidence of structural disease that is likely toexplain the symptoms

4. History of IBS-D and dyspepsia symptoms for at least 12 weeks

5. Agree to use contraception throughout study period, unless postmenopausal orsurgically sterile (females only)

6. Able to understand the nature and purpose of the study including potential risks andside effects

7. Willing to consent to study participation and to comply with study requirements

8. Successful completion of 2-week placebo-only run-in period, defined as ≥90% productcompliance and completion of required questionnaires

Exclusion Criteria:

1. Major gastrointestinal complication, e.g. Crohn's disease or ulcer

2. Prior abdominal surgery with the exception of hernia repair and appendectomy

3. Subjects over 60 years who have not had a sigmoidoscopy or colonoscopy in the past 10years

4. Clinically significant systemic disease

5. Life expectancy < 6 months

6. Pregnant female or breastfeeding

7. Lactose intolerance

8. Immunodeficient subjects

9. Anti-psychotic medication within the prior 3 months or major psychiatric disorderwithin the past 2 years

10. Systemic steroids within the prior month

11. Current treatment with nasogastric tube, ostomy, or parenteral nutrition

12. Use of proton pump inhibitors

13. Eating disorder

14. Recent (< 2 weeks) antibiotic administration

15. History of alcohol, drug, or medication abuse

16. Daily consumption of probiotics, fermented milk, and/or yogurt

17. Known allergies to any substance in the study product

18. Participation in another study with any investigational product within 3 months ofscreening